CD8A and neoplasm: Sitkovsky and colleagues (Kjaergaard et al., 2018) demonstrated that gene deletion of the A2AR, as well as the A2AR antagonist, removes the tumor-induced immunosuppression of the tumor-reactive CD8+ T cells.